Cephacare Flavour 250 mg Tablets for Dogs

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Cefalexin

Available from:

Animalcare Ltd

ATC code:

QJ01DB01

INN (International Name):

Cefalexin

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Antimicrobial

Authorization status:

Authorized

Authorization date:

2008-12-19

Summary of Product characteristics

Revised: August 2022
AN: 01024/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Cephacare flavour 250 mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
250 mg cefalexin as cefalexin monohydrate.
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
Beige, flat tablets with a break mark on one side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections of the respiratory tract, gastro-intestinal
tract, urogenital tract,
the skin and localised infections in soft tissue caused by bacteria
sensitive to
cefalexin.
4.3
CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active substance,
to other
cephalosporins, to other substances of the

-lactam group or to any of the excipients.
Do not use in rabbits, gerbils, guinea pigs and hamsters.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Revised: August 2022
AN: 01024/2022
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing and take
into account
official and local antimicrobial policies.
Use of the product deviating from the instructions given in the SPC
may increase the
prevalence of bacteria resistant to cefalexin and may decrease the
effectiveness of
treatment with penicillins, due to the potential for cross resistance.
In the case of an allergic reaction, treatment should be withdrawn.
As with other antibiotics which are excreted mainly by the kidneys,
unnecessary
accumulation may occur in the body when renal function is impaired. In
cases of
known renal insufficiency the dose should be reduced, antimicrobials
known to be
nephrotoxic should not be administered concurrently and the product
should be used
only according to a risk/benefit assessment by the responsible
veterinarian.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETE